NEW YORK (GenomeWeb) – Belgium-based genomic testing company OncoDNA said today that it has agreed to supply tumor molecular profiling analysis for non-profit clinical research organization SOLTI's AGATA breast cancer screening program.
AGATA is a pilot genomic screening program pioneered by SOLTI in Spain that aims to refer breast cancer patients to clinical trials based on their tumor molecular profile. Under the terms of the agreement, OncoDNA will customize its OncoKDM (Knowledge Drive Medicine) software-as-a-service platform to answer the specific needs of the AGATA trial. This will include integrating three types of DNA data — Illumina NGS, Ion Torrent NGS, and analysis using Sequenom's Massarray — as well as RNA expression profiling and proteomic data.
OncoKDM will use these analyses to generate a theranostic report that can then be used to guide treatment in different clinical trials for breast cancer patients within the AGATA program.
"We are excited to work together to enhance the outcomes we provide through the AGATA program to better direct patients to clinical trials according to their tumor profile," said SOLTI President Eva Ciruelos in a statement. OncoDNA Chief Technology Officer Jean-François Laes added that the collaboration is the first the company has announced for OncoKDM.